Semaglutide appetite regulation is best understood through integrated GLP-1 biology, receptor signaling, gastrointestinal–neural communication, and central energy-balance networks. Its pharmacology intersects with mechanism, clinical pharmacology, and appetite regulation through pathways involving meal-related signals, satiety processing, endocrine communication, and metabolic state.
The appetite-related pharmacology also connects gastrointestinal physiology with pharmacodynamics, pharmacokinetics, and glycemic control. Peripheral receptor signaling can interact with vagal sensory pathways and central circuits involved in energy balance, while endocrine and metabolic signals provide additional context. These relationships are relevant to obesity, weight management, and related metabolic physiology.
Appetite responses are therefore multidimensional rather than attributable to one isolated pathway. Gastrointestinal feedback, neural integration, endocrine signaling, insulin sensitivity, glucose regulation, and temporal drug exposure can interact across biological systems. This framework connects appetite regulation with insulin resistance, metabolic outcomes, and mechanistic interpretation of evidence from clinical trials without assuming uniform responses.
Appetite regulation emerges from coordinated peripheral and central signals rather than a single appetite center. Semaglutide engages GLP-1 biology through receptor-mediated signaling that can intersect with gastrointestinal sensory pathways, vagal communication, and central energy-balance circuits. The broader mechanism is therefore connected to appetite regulation, pharmacodynamics, and clinical pharmacology, while metabolic context involving insulin resistance and glycemic control can influence the physiological background in which appetite signals are processed.
Peripheral signaling can modify how gastrointestinal information is transmitted to the nervous system, while central networks integrate hormonal, nutrient, and visceral inputs. Relevant pathways include vagal afferent signaling, brainstem processing, hypothalamic energy-balance circuits, and interactions among endocrine mediators. These relationships connect GLP-1 biology with appetite regulation, mechanism, pharmacodynamics, and metabolic outcomes, while type 2 diabetes and obesity provide distinct metabolic contexts.
Appetite is also shaped by interactions between energy intake, glucose handling, insulin signaling, and gastrointestinal feedback. Consequently, semaglutide-associated receptor signaling should be interpreted within a systems framework involving insulin resistance, glycemic variability, appetite regulation, and clinical pharmacology. Pharmacokinetics and pharmacodynamics add temporal dimensions, while weight management and obesity represent clinical contexts rather than isolated mechanistic pathways.
| Physiological component | Mechanistic relationship | Relevant domain |
|---|---|---|
| Peripheral GLP-1 signaling | Receptor-mediated sensory and endocrine signaling | GLP-1 biology |
| Central energy-balance circuits | Integration of hormonal, nutrient, and visceral information | Appetite physiology |
| Metabolic state | Modifies the context in which appetite signals are interpreted | Insulin and glucose physiology |
The gastrointestinal tract functions as a sensory and endocrine interface linking nutrient exposure with neural and hormonal communication. Semaglutide-related GLP-1 biology intersects with gastrointestinal signaling and mechanism through pathways that include enteroendocrine activity and visceral sensory information. These processes are relevant to appetite regulation, pharmacodynamics, and clinical pharmacology, with broader connections to glycemic control and metabolic physiology.
Vagal afferents provide an important communication route between gastrointestinal tissues and the brainstem. Their signals can be integrated with circulating hormones and nutrient-related information before influencing higher-order appetite networks. This creates mechanistic links among GLP-1 biology, appetite regulation, mechanism, pharmacodynamics, and pharmacokinetics. The resulting physiology is also relevant to obesity and weight management, although these contexts do not imply a uniform response.
Gastrointestinal signaling should not be reduced to one physical process or one receptor location. Neural transmission, endocrine secretion, gastrointestinal motility, nutrient sensing, and central integration may all contribute to temporal appetite physiology. Accordingly, clinical pharmacology, pharmacokinetics, pharmacodynamics, and appetite regulation provide complementary perspectives, while glycemic variability and metabolic outcomes help contextualize interconnected metabolic signaling.
| Signal pathway | Primary role |
|---|---|
| Enteroendocrine signaling | Links intestinal nutrient sensing with circulating hormonal signals |
| Vagal afferent signaling | Conveys visceral information toward brainstem processing networks |
| Brainstem integration | Combines visceral, hormonal, and metabolic information |
Vagal pathways form a major neural interface between the gastrointestinal tract and central nervous system. Semaglutide-associated GLP-1 biology can be considered alongside visceral sensory signaling, mechanism, and pharmacodynamics when examining appetite-related physiology. These pathways intersect with appetite regulation, clinical pharmacology, and pharmacokinetics, while metabolic signals associated with glycemic control provide additional physiological context.
Vagal afferent neurons transmit information from visceral tissues toward the nucleus tractus solitarius and related brainstem structures. This signaling is part of a broader network that integrates gastrointestinal, endocrine, and nutrient-derived information. Semaglutide pharmacology can therefore be examined through GLP-1 biology, mechanism, pharmacodynamics, and appetite regulation, with obesity, weight management, and metabolic outcomes representing broader physiological contexts.
The vagal system does not operate independently of circulating endocrine signals or central metabolic sensing. Brainstem information can be relayed to hypothalamic and other forebrain networks where appetite, energy expenditure, and behavioral signals are coordinated. This systems-level interpretation links appetite regulation with clinical pharmacology, pharmacokinetics, pharmacodynamics, insulin resistance, and glycemic variability without attributing appetite physiology to a single pathway.
| Neural structure | Functional role | Physiological context |
|---|---|---|
| Vagal afferents | Visceral sensory transmission | Gastrointestinal signaling |
| Nucleus tractus solitarius | Brainstem integration of visceral inputs | Meal-related signaling |
| Hypothalamic networks | Higher-order energy-balance integration | Appetite physiology |
Hypothalamic circuits integrate hormonal, nutrient, and neural information to coordinate energy balance. Semaglutide-related GLP-1 biology intersects with this broader architecture through receptor signaling and communication with central appetite networks. The mechanistic framework includes mechanism, pharmacodynamics, and appetite regulation, while clinical pharmacology and pharmacokinetics describe temporal exposure and response relationships.
Important hypothalamic populations include neurons involved in orexigenic and anorexigenic signaling, with arcuate nucleus pathways integrating circulating metabolic cues. These circuits interact with brainstem and peripheral signals rather than functioning as an isolated switch. Consequently, GLP-1 biology, appetite regulation, mechanism, pharmacodynamics, and metabolic outcomes should be interpreted as connected components of a distributed energy-balance network.
Hypothalamic signaling is influenced by metabolic conditions such as insulin resistance, glucose availability, and adiposity-associated endocrine signals. These interactions connect insulin resistance, glycemic control, obesity, and weight management with semaglutide pharmacology. Pharmacokinetics and pharmacodynamics add exposure-response timing, while clinical trials provide evidence that can be interpreted mechanistically without reducing complex physiology to a single pathway.
| Central network | Mechanistic function |
|---|---|
| Arcuate nucleus | Integrates metabolic and hormonal signals |
| Orexigenic pathways | Participate in hunger and energy-intake signaling |
| Anorexigenic pathways | Participate in satiety and energy-balance signaling |
Appetite is regulated by a network of endocrine signals that communicate nutritional and metabolic state. Semaglutide is related to GLP-1 biology, but appetite physiology also includes insulin, glucagon, leptin, ghrelin, peptide YY, and other mediators. The relevant mechanism therefore intersects with appetite regulation, pharmacodynamics, and clinical pharmacology, while glycemic control provides metabolic context.
Endocrine signals can alter hypothalamic and brainstem circuit activity, modify nutrient sensing, and influence the interpretation of gastrointestinal information. Semaglutide-related receptor signaling should therefore be considered within a network involving GLP-1 biology, appetite regulation, mechanism, pharmacodynamics, and pharmacokinetics. Connections with insulin resistance and metabolic outcomes further demonstrate why endocrine appetite physiology is metabolically integrated.
Endocrine responses can vary according to nutritional state, metabolic phenotype, receptor signaling, gastrointestinal physiology, and temporal exposure. This variability makes clinical pharmacology, pharmacokinetics, and pharmacodynamics important interpretive frameworks. Related contexts include obesity, type 2 diabetes, weight management, and clinical trials, where mechanistic evidence can help distinguish receptor activity from downstream physiological effects.
| Endocrine signal | Appetite-related role |
|---|---|
| GLP-1 | Participates in nutrient-linked endocrine and neural signaling |
| Insulin | Conveys metabolic and nutrient-availability information |
| Ghrelin | Contributes to hunger-related signaling |
| Leptin | Conveys longer-term energy-store information |
Appetite is closely connected with systemic metabolic state, including glucose availability, insulin signaling, lipid metabolism, and energy balance. Semaglutide pharmacology can be examined through GLP-1 biology, mechanism, and clinical pharmacology, while insulin resistance, glycemic control, and glycemic variability describe interconnected metabolic conditions that influence appetite-related signaling.
Changes in nutrient handling can alter endocrine and neural feedback, creating reciprocal relationships between appetite and metabolism. These relationships involve appetite regulation, metabolic outcomes, pharmacodynamics, and pharmacokinetics. The same receptor-mediated pharmacology may therefore be considered from multiple perspectives, including gastrointestinal signaling, endocrine physiology, glucose regulation, and energy-balance networks, without treating any one pathway as sufficient to explain the whole response.
Metabolic context can differ substantially across physiological states and disease phenotypes. Obesity, type 2 diabetes, and weight management involve overlapping but nonidentical metabolic processes. Accordingly, clinical pharmacology, GLP-1 biology, mechanism, appetite regulation, and clinical trials provide complementary frameworks for interpreting metabolic contributions to appetite physiology.
| Metabolic factor | Appetite relevance | Associated physiology |
|---|---|---|
| Glucose availability | Influences nutrient sensing and endocrine feedback | Glycemic physiology |
| Insulin signaling | Conveys nutrient and metabolic-state information | Insulin resistance |
| Energy balance | Integrates intake, expenditure, and energy stores | Adiposity physiology |
Pharmacokinetics describes semaglutide exposure over time, whereas pharmacodynamics describes the biological consequences of receptor engagement. Together they provide a framework for interpreting appetite-related physiology through pharmacokinetics, pharmacodynamics, clinical pharmacology, and mechanism. These concepts connect exposure with GLP-1 biology, appetite regulation, and downstream endocrine and gastrointestinal signaling.
Temporal exposure does not necessarily translate instantaneously into every physiological effect. Receptor occupancy, intracellular signaling, neural integration, endocrine feedback, and downstream adaptation can create distinct temporal relationships between drug concentration and observed physiology. Thus, pharmacokinetics, pharmacodynamics, GLP-1 biology, appetite regulation, and clinical pharmacology should be interpreted together rather than treated as interchangeable concepts.
Exposure-response relationships may also vary across individuals because of biological heterogeneity, pharmacokinetic variation, receptor sensitivity, metabolic state, and gastrointestinal physiology. This connects pharmacokinetics and pharmacodynamics with obesity, type 2 diabetes, insulin resistance, and metabolic outcomes. Mechanistic interpretation therefore requires attention to temporal exposure, biological response, and variability rather than assuming a fixed concentration-effect relationship.
| PK/PD concept | Appetite-related interpretation |
|---|---|
| Exposure | Represents systemic drug concentration over time |
| Receptor signaling | Represents pharmacodynamic engagement of GLP-1 receptors |
| Downstream response | Includes integrated neural, endocrine, and gastrointestinal physiology |
Appetite physiology unfolds across multiple timescales, from rapid meal-related sensory signaling to slower endocrine and metabolic adaptation. Semaglutide exposure can therefore be considered through pharmacokinetics and pharmacodynamics, while GLP-1 biology, mechanism, and appetite regulation describe receptor and systems-level processes. Clinical pharmacology integrates these temporal dimensions with gastrointestinal and metabolic physiology.
Early receptor signaling may coexist with slower changes in neural processing, gastrointestinal adaptation, endocrine feedback, and metabolic state. This distinction is important because exposure stabilization and physiological response stabilization are related but not identical concepts. The framework links pharmacokinetics, pharmacodynamics, clinical pharmacology, appetite regulation, and metabolic outcomes, with glycemic variability providing another example of temporally dynamic physiology.
Temporal adaptation may differ between individuals because biological systems have different baseline states, receptor responsiveness, gastrointestinal characteristics, endocrine feedback, and metabolic conditions. Relevant contexts include obesity, weight management, type 2 diabetes, and insulin resistance. Mechanistic evidence from clinical trials can inform these relationships, but temporal physiology should not be inferred from a single pharmacokinetic or pharmacodynamic measurement.
| Timescale | Physiological process |
|---|---|
| Rapid | Meal-related gastrointestinal and neural signaling |
| Intermediate | Endocrine and receptor-mediated signaling integration |
| Longer-term | Metabolic and energy-balance adaptation |
Appetite-related responses can vary because pharmacological exposure and biological sensitivity are not identical across individuals. Relevant determinants include pharmacokinetics, pharmacodynamics, receptor signaling, gastrointestinal physiology, endocrine state, and metabolic phenotype. These factors connect clinical pharmacology with GLP-1 biology, mechanism, and appetite regulation, while obesity and type 2 diabetes provide heterogeneous clinical contexts.
Variability may arise from differences in systemic exposure, receptor responsiveness, neural integration, gastrointestinal signaling, metabolic state, and concurrent physiological feedback. Consequently, an exposure-response relationship should be viewed as a distribution rather than a single invariant curve. This perspective connects pharmacokinetics, pharmacodynamics, clinical pharmacology, insulin resistance, and glycemic variability with broader metabolic outcomes.
Measurement itself can contribute to apparent variability because appetite is multidimensional and influenced by hunger, satiety, food preference, meal timing, gastrointestinal sensations, and behavioral context. Mechanistic interpretation therefore benefits from combining appetite regulation, GLP-1 biology, pharmacokinetics, pharmacodynamics, and clinical pharmacology. Evidence from clinical trials can characterize distributions and associations without implying that every individual follows the same physiological trajectory.
| Source of variability | Potential mechanistic influence | Interpretive domain |
|---|---|---|
| Pharmacokinetic variability | Different systemic exposure profiles | PK |
| Receptor or neural sensitivity | Different downstream signaling responses | PD |
| Metabolic phenotype | Different endocrine and energy-balance context | Systems physiology |
Satiety represents an integrated physiological state generated by gastrointestinal, endocrine, neural, and metabolic information. Semaglutide-related GLP-1 biology can intersect with these systems through receptor-mediated signaling, while mechanism, appetite regulation, and pharmacodynamics provide complementary explanatory frameworks. Clinical pharmacology and pharmacokinetics add the temporal dimension required to interpret changing receptor exposure.
Gastrointestinal signals can reach the brain through vagal afferents and circulating endocrine mediators, while hypothalamic and brainstem networks integrate these inputs with energy-state information. This creates relationships among GLP-1 biology, appetite regulation, mechanism, pharmacodynamics, and metabolic outcomes. The mechanistic concept of satiety therefore encompasses distributed signaling rather than a single receptor event or isolated gastrointestinal process.
Satiety-related physiology can also interact with glucose and insulin signaling, making metabolic context relevant to interpretation. Insulin resistance, glycemic control, and glycemic variability can alter the background against which appetite signals operate. In turn, obesity, weight management, and type 2 diabetes represent complex physiological settings. Mechanistic evidence should therefore distinguish receptor activity, integrated satiety signaling, and downstream systemic physiology.
| Satiety component | Mechanistic contribution |
|---|---|
| Gastrointestinal signaling | Provides meal-related visceral and endocrine information |
| Vagal pathways | Transmit visceral sensory information to brainstem circuits |
| Central integration | Combines hormonal, neural, and metabolic signals |
Semaglutide appetite pharmacology is best represented as a network linking receptor signaling, gastrointestinal physiology, neural communication, endocrine feedback, and metabolism. GLP-1 biology, mechanism, and appetite regulation describe biological pathways, while pharmacokinetics, pharmacodynamics, and clinical pharmacology describe exposure and response relationships. Insulin resistance and glycemic control add metabolic context.
At the gastrointestinal level, nutrient sensing and visceral signaling communicate with the nervous system through endocrine and vagal routes. At the central level, brainstem and hypothalamic networks integrate these inputs with energy-store and metabolic signals. The resulting framework connects GLP-1 biology, appetite regulation, mechanism, pharmacodynamics, and metabolic outcomes. Pharmacokinetics explains exposure persistence while pharmacodynamics describes downstream biological activity.
This integrated model also explains why appetite-related physiology cannot be interpreted independently from metabolic phenotype or temporal exposure. Obesity, weight management, type 2 diabetes, and glycemic variability involve interconnected physiological systems with differing baseline characteristics. Clinical trials and effectiveness overview can provide empirical context, while mechanistic analysis remains focused on receptor signaling, exposure-response relationships, temporal adaptation, and biological variability.
| System level | Key components | Pharmacological connection |
|---|---|---|
| Peripheral | GI tract, endocrine cells, visceral sensors | GLP-1 receptor signaling |
| Neural | Vagal afferents, brainstem, hypothalamus | Integrated pharmacodynamics |
| Systemic | Metabolism, endocrine state, energy balance | Exposure-response physiology |
Mechanistic evidence for semaglutide appetite pharmacology can include receptor biology, physiological experiments, pharmacokinetic analyses, pharmacodynamic biomarkers, and controlled clinical observations. Clinical trials provide an important evidence context, while GLP-1 biology, mechanism, pharmacokinetics, and pharmacodynamics help explain how observed physiological signals may relate to drug exposure. Clinical pharmacology integrates these evidence streams without treating association as proof of a single causal pathway.
Interpretation should distinguish direct receptor-mediated effects from downstream consequences of interconnected physiology. Gastrointestinal signaling, endocrine feedback, neural adaptation, glucose regulation, and metabolic state can all influence appetite-related measurements. These relationships connect appetite regulation, glycemic control, insulin resistance, and metabolic outcomes with GLP-1 biology and mechanism. Temporal exposure adds another layer of interpretation through pharmacokinetics and pharmacodynamics.
Evidence can also demonstrate heterogeneity rather than one universal physiological pattern. Variability may reflect pharmacokinetic exposure, receptor sensitivity, gastrointestinal signaling, endocrine state, metabolic phenotype, or measurement characteristics. This makes clinical pharmacology, pharmacokinetics, pharmacodynamics, and appetite regulation useful frameworks for interpreting obesity, weight management, and type 2 diabetes evidence without making patient-level predictions.
| Evidence type | Mechanistic information |
|---|---|
| Receptor studies | GLP-1 receptor signaling and downstream pathways |
| PK/PD studies | Exposure and biological-response relationships |
| Clinical trials | Integrated physiological observations within defined study populations |
Appetite regulation is a distributed physiological process involving gastrointestinal sensory signals, endocrine hormones, vagal afferent pathways, brainstem integration, hypothalamic circuits, and broader metabolic information. GLP-1 receptor signaling is one component within this network. Hunger and satiety are influenced by nutrient availability, energy stores, glucose and insulin physiology, gastrointestinal feedback, and neural processing. Consequently, appetite should be understood as an integrated state emerging from multiple interacting systems rather than as the output of one isolated receptor, organ, or neurotransmitter pathway.
The gastrointestinal tract communicates with the nervous system through visceral sensory pathways, endocrine signals, and nutrient-sensing mechanisms. Vagal afferent neurons transmit information from gastrointestinal tissues toward brainstem structures, where signals can be integrated with circulating hormones and other metabolic inputs. Brainstem information can subsequently interact with hypothalamic and higher-order networks involved in energy balance. This arrangement allows meal-related gastrointestinal information to influence appetite physiology without requiring a single direct pathway between the digestive tract and conscious appetite perception.
Vagal pathways provide an important neural connection between visceral organs and the central nervous system. Vagal afferent neurons detect aspects of gastrointestinal mechanical, chemical, and hormonal signaling and convey this information toward brainstem nuclei such as the nucleus tractus solitarius. These signals can be integrated with endocrine and nutrient-related information before influencing broader energy-balance networks. Vagal signaling is therefore one component of appetite physiology, operating alongside circulating hormones, hypothalamic circuits, gastrointestinal processes, and other central neural systems.
The hypothalamus contains interconnected neuronal populations that integrate hormonal, nutrient, and neural information related to energy balance. The arcuate nucleus includes pathways associated with hunger-promoting and satiety-related signaling, while other hypothalamic regions coordinate information about energy availability and physiological state. GLP-1-related signaling can interact with this broader network through central and peripheral mechanisms. Hypothalamic appetite physiology is therefore not an isolated GLP-1 process; it represents one level of a distributed system involving brainstem inputs, endocrine signals, nutrient sensing, and metabolic feedback.
Endocrine signals communicate nutritional state, energy availability, and longer-term energy stores to the brain and peripheral tissues. Relevant mediators include GLP-1, insulin, glucagon, leptin, ghrelin, peptide YY, and other gastrointestinal or metabolic hormones. These signals can influence brainstem and hypothalamic circuits, interact with nutrient sensing, and modify the interpretation of gastrointestinal information. Endocrine appetite physiology is therefore dynamic and context-dependent, with different hormonal signals contributing at different timescales rather than one hormone independently determining hunger or satiety.
Appetite and metabolism are closely interconnected. Glucose availability, insulin signaling, lipid metabolism, energy stores, and nutrient flux can alter endocrine and neural feedback associated with hunger and satiety. Conversely, appetite-related signaling influences nutrient intake and therefore changes the metabolic environment in which endocrine pathways operate. Insulin resistance, dysglycemia, and adiposity can modify this background physiology. A mechanistic interpretation of appetite therefore considers metabolic state alongside gastrointestinal signaling, endocrine communication, neural circuits, and receptor-mediated pharmacology.
Pharmacokinetics describes drug exposure over time, while pharmacodynamics describes the biological effects associated with that exposure. Appetite-related responses may not occur in a simple one-to-one relationship with circulating concentration because receptor signaling, neural integration, endocrine feedback, gastrointestinal physiology, and downstream adaptation can have different temporal characteristics. PK/PD analysis therefore helps distinguish exposure from biological response. It also provides a framework for understanding why changes in systemic concentration, receptor engagement, and observable appetite-related physiology may follow related but nonidentical time courses.
Interindividual variability can arise from differences in pharmacokinetic exposure, receptor responsiveness, gastrointestinal physiology, endocrine state, metabolic phenotype, neural signaling, and baseline energy-balance regulation. Measurement factors can contribute as well because appetite includes several dimensions, including hunger, satiety, food preference, meal-related sensations, and behavioral context. Consequently, a population-level exposure-response relationship represents a distribution rather than a universal biological rule. Mechanistic interpretation should account for this heterogeneity rather than assuming that similar exposure necessarily produces identical appetite-related physiological responses.
A mechanistic interpretation describes how physiological signals could participate in generating or modifying satiety without assuming that one pathway explains the entire phenomenon. Relevant components include GLP-1 receptor signaling, gastrointestinal nutrient sensing, vagal afferent communication, brainstem integration, hypothalamic circuits, endocrine feedback, and metabolic state. The goal is to distinguish receptor activity from downstream physiological responses and from behavioral measurements. This approach recognizes that satiety is an emergent state produced by coordinated neural, endocrine, gastrointestinal, and metabolic processes.
GLP-1 physiology refers specifically to biological signaling associated with the endogenous GLP-1 system, including receptor-mediated effects in relevant tissues. Appetite physiology is broader and incorporates GLP-1 alongside numerous gastrointestinal hormones, neural pathways, nutrient signals, metabolic feedback mechanisms, and central energy-balance circuits. Therefore, GLP-1 signaling can contribute to appetite regulation without being synonymous with it. Understanding the distinction prevents complex appetite responses from being attributed entirely to one hormone or receptor system.
Mechanistic evidence helps connect observed physiological phenomena with underlying biological processes. Receptor studies can characterize GLP-1 signaling, physiological experiments can examine gastrointestinal or neural pathways, and PK/PD studies can relate exposure to biological responses. Clinical studies add information about integrated human physiology within defined populations. No single evidence type captures every level of appetite regulation. Combining these approaches helps distinguish direct pharmacological effects from downstream adaptations, associations, and context-dependent physiological responses.
Appetite regulation is a systems-level process involving peripheral tissues, endocrine signals, neural communication, gastrointestinal physiology, and central energy-balance networks. Gastrointestinal information can reach the brain through vagal and hormonal routes, while brainstem and hypothalamic circuits integrate those signals with nutrient availability and energy-store information. Metabolic state further modifies the signaling environment. Semaglutide-related GLP-1 receptor pharmacology can therefore be considered one component within a larger network rather than an isolated mechanism. PK and PD provide additional temporal context for this integrated physiology.
Clinical evidence can demonstrate associations among drug exposure, physiological biomarkers, gastrointestinal phenomena, appetite-related measurements, and metabolic variables, but mechanistic interpretation requires attention to study design and biological plausibility. Receptor pharmacology and PK/PD data can help explain potential pathways, while clinical observations show how multiple systems behave together in humans. Differences among study populations can also affect interpretation. Mechanistic analysis therefore connects clinical observations with established physiology while avoiding the assumption that every observed appetite-related change is caused by one isolated biological pathway.